Before undertaking further clinical trials, in vivo chondrosarcoma xenograft studies could examine the effects of multiple doses with talazoparib and olaparib in tumors with a mixed selection of IDH mutation statuses. This evidence concerns the gene IDH1 and chondrosarcoma.